This course is part of the Navigating GLP-1 RA Therapy to Improve Health Outcomes in Type 2 Diabetes: Practical Considerations for Primary Care curriculum.
Interactive Learning
0.25 CME Credit
Interactive Learning: Navigating GLP-1 RA Therapy to Improve Health Outcomes in Type 2 Diabetes: Practical Considerations for Primary CareThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
This infographic reviews the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) approved for treatment of type 2 diabetes, including their glycemic and extraglycemic effects. Clinical practice recommendations for the use of GLP-1 RAs are provided, along with top tips for initiating therapy effectively and safely in the clinic.
CME Information
0.25 AMA PRA Category 1 Credits™, 0.25 ABIM MOC or 0.25 AANP, including 0.25 AANP Pharm
Release Date: 11/1/2024
Expiration Date: 11/1/2025
Topics
Learning Objectives
Upon completion of this activity, participants will be able to:
- Differentiate between available GLP-1 RAs with reference to glycemic lowering efficacy, weight effects, and CV/renal benefits
- Initiate GLP-1 RA therapy in appropriate individuals according to guidelines, as part of a comprehensive treatment strategy
- Discuss and implement strategies for mitigating and treating potential side effects of GLP-1 RA therapy
Faculty
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor and Diabetologist
Department of Clinical Sciences and Community Health
Touro University
Vallejo, California
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Jay H Shubrook, DO, FAAFP, FACOFP: Advisor for Eli Lilly, Madrigal, and Nevro. Consultant for Abbott, Bayer, and Novo Nordisk Inc.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
CME Information
AMA PRA Category 1 Credits™
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308. This activity is approved for 0.25 contact hour(s) (which includes 0.25 hour(s) of pharmacology).
Designation Statement
This activity is approved for 0.25 contact hour, which includes 0.25 hour of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Obtaining Credit
Supporters and Partners
Supported by
Novo Nordisk Inc.
Education Partner
Institute for Medical and Nursing Education, Inc.
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.